Cash on Hand Totals $17.8 million at June 30
Investor Conference Call Scheduled for September 5
NAPA, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced financial results for the quarter ended June 30, 2008.
Revenue for the quarter ended June 30, 2008 was $691,000, compared with $471,000 reported in the second quarter of 2007.
Net income for the quarter ended June 30, 2008 totaled $257,000, or $0.03 per share compared to a net loss of $397,000 a loss of $0.05 per share in the second quarter of 2007. Net income for the quarter ended June 30, 2008 included other income of $1,125,000 from the previously announced settlement with Triax Aesthetics LLC and a service provider.
Cash and cash equivalents totaling $17,803,000, or $2.33 per share at June 30, 2008 represent the resources necessary to meet operating requirements for the foreseeable future.
Senetek's Board of Directors will meet on August 28, 2008. Matters to be addressed include a capital restructure to facilitate both a possible share buyback and dividend program and a Nominating Committee review of Board candidates.
Senetek will conduct a teleconference call for investors on Friday,
September 5, 2008 at 9:00 a.m. Pacific, 12:00 p.m. Eastern to provide an
update to include:
* Pyratine-6(TM) -- current success in U.S. physician market and Q4 2008
* Invicorp(R) EU -- effect of Ardana Bioscience Ltd. insolvency.
* Invicorp(R) US -- Plethora Solutions Ltd. report on status of regulatory
* Reliaject(R) -- update on Ranbaxy's progress.
* Corporate and Product Public Relations.
The domestic dial-in number is 877-593-8638; the international dial-in
number is 706-634-9240, conference ID 60464120. Mr. Frank J.
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved